Compare AbbVie Inc (ABBV) vs Symbotic Inc (SYM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Symbotic Inc — how do they compare? AbbVie Inc trades at $253.9 (market cap $449.91B), while Symbotic Inc trades at $40.39 (market cap $5.26B). The key difference: AbbVie Inc is far larger — about 85.5× Symbotic Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals.
| ABBV | SYM | |
|---|---|---|
Market Cap | $449.91B | $5.26B |
Sector | Health | Technology |
52-Week High | $261.07 | $87.30 |
52-Week Low | $184.85 | $38.57 |
Enterprise Value | $513.38B | $3.25B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
SYM trades at $44.46, up 4.02% in the last session, with a neutral technical signal and bearish moving averages. The stock shows mixed earnings, beating estimates in Q3 and Q4 2025 but missing in Q1 2026, while revenue grew to $2.25B in 2025. Recent news highlights the acquisition of ARMS Innovations, expanding its warehouse automation solutions, amid high investor interest in robotics stocks.
The outlook is cautiously optimistic with a consensus price target of $57.50, but risks include negative net income margins and high valuation multiples like EV/EBITDA of 246.96. Upside potential hinges on execution in the growing automation market, while downside risks involve competitive pressures and profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
